Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 69.46 Billion KRW | -5.93% |
| 2022 | 72.09 Billion KRW | 0.4% |
| 2021 | 71.81 Billion KRW | -1.74% |
| 2020 | 73.08 Billion KRW | 4.71% |
| 2019 | 69.79 Billion KRW | 9.69% |
| 2018 | 63.62 Billion KRW | -3.32% |
| 2017 | 65.81 Billion KRW | 0.03% |
| 2016 | 65.79 Billion KRW | 10.07% |
| 2015 | 59.77 Billion KRW | 10.28% |
| 2014 | 54.2 Billion KRW | 8.2% |
| 2013 | 50.09 Billion KRW | 11.02% |
| 2012 | 45.12 Billion KRW | 11.44% |
| 2011 | 40.48 Billion KRW | -18.15% |
| 2010 | 49.46 Billion KRW | 12.72% |
| 2009 | 43.88 Billion KRW | -0.84% |
| 2008 | 44.25 Billion KRW | -5.16% |
| 2007 | 46.66 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 16.21 Billion KRW | -6.13% |
| 2024 Q2 | 18.29 Billion KRW | 12.82% |
| 2024 Q3 | 60.72 Billion KRW | -4.73% |
| 2023 Q4 | 17.27 Billion KRW | 197.11% |
| 2023 Q1 | 16.1 Billion KRW | -18.88% |
| 2023 Q2 | -17.58 Billion KRW | -209.19% |
| 2023 FY | 67.82 Billion KRW | -5.93% |
| 2023 Q3 | -17.78 Billion KRW | -1.16% |
| 2022 Q3 | 18.03 Billion KRW | 3.82% |
| 2022 FY | 72.09 Billion KRW | 0.4% |
| 2022 Q1 | 16.84 Billion KRW | -10.69% |
| 2022 Q2 | 17.36 Billion KRW | 3.08% |
| 2022 Q4 | 19.84 Billion KRW | 10.08% |
| 2021 Q3 | 17.96 Billion KRW | -3.7% |
| 2021 Q4 | 18.86 Billion KRW | 5.01% |
| 2021 FY | 71.81 Billion KRW | -1.74% |
| 2021 Q1 | 16.32 Billion KRW | -16.77% |
| 2021 Q2 | 18.65 Billion KRW | 14.25% |
| 2020 Q3 | 17.73 Billion KRW | 0.33% |
| 2020 Q4 | 19.61 Billion KRW | 10.63% |
| 2020 FY | 73.08 Billion KRW | 4.71% |
| 2020 Q1 | 18.05 Billion KRW | -14.5% |
| 2020 Q2 | 17.67 Billion KRW | -2.12% |
| 2019 Q3 | 16.7 Billion KRW | 3.94% |
| 2019 FY | 69.79 Billion KRW | 9.69% |
| 2019 Q1 | 15.89 Billion KRW | -8.82% |
| 2019 Q2 | 16.07 Billion KRW | 1.11% |
| 2019 Q4 | 21.12 Billion KRW | 26.44% |
| 2018 Q2 | 15 Billion KRW | -1.88% |
| 2018 Q1 | 15.28 Billion KRW | -12.87% |
| 2018 FY | 63.62 Billion KRW | -3.32% |
| 2018 Q4 | 17.43 Billion KRW | 9.6% |
| 2018 Q3 | 15.9 Billion KRW | 6.02% |
| 2017 Q4 | 17.54 Billion KRW | 5.31% |
| 2017 Q2 | 15.5 Billion KRW | -3.71% |
| 2017 Q1 | 16.1 Billion KRW | -17.29% |
| 2017 Q3 | 16.66 Billion KRW | 7.46% |
| 2017 FY | 65.81 Billion KRW | 0.03% |
| 2016 Q3 | 16.61 Billion KRW | 13.14% |
| 2016 Q4 | 19.46 Billion KRW | 17.17% |
| 2016 FY | 65.79 Billion KRW | 10.07% |
| 2016 Q1 | 15.02 Billion KRW | -3.91% |
| 2016 Q2 | 14.68 Billion KRW | -2.27% |
| 2015 Q2 | 14.7 Billion KRW | 8.5% |
| 2015 Q4 | 15.63 Billion KRW | -1.54% |
| 2015 Q3 | 15.88 Billion KRW | 8.02% |
| 2015 FY | 59.77 Billion KRW | 10.28% |
| 2015 Q1 | 13.55 Billion KRW | -10.86% |
| 2014 Q4 | 15.2 Billion KRW | 14.95% |
| 2014 Q3 | 13.22 Billion KRW | 2.28% |
| 2014 Q2 | 12.92 Billion KRW | 0.65% |
| 2014 Q1 | 12.84 Billion KRW | -1.53% |
| 2014 FY | 54.2 Billion KRW | 8.2% |
| 2013 FY | 50.09 Billion KRW | 11.02% |
| 2013 Q3 | 12.58 Billion KRW | -2.1% |
| 2013 Q2 | 12.85 Billion KRW | 10.68% |
| 2013 Q1 | 11.61 Billion KRW | -10.74% |
| 2013 Q4 | 13.04 Billion KRW | 3.67% |
| 2012 FY | 45.12 Billion KRW | 11.44% |
| 2012 Q4 | 13.01 Billion KRW | 16.79% |
| 2012 Q3 | 11.13 Billion KRW | 6.76% |
| 2012 Q2 | 10.43 Billion KRW | -0.96% |
| 2012 Q1 | 10.53 Billion KRW | 5.33% |
| 2011 Q3 | 9.57 Billion KRW | -12.13% |
| 2011 Q1 | 10.22 Billion KRW | -13.73% |
| 2011 Q4 | 10 Billion KRW | 4.42% |
| 2011 Q2 | 10.9 Billion KRW | 6.67% |
| 2011 FY | 40.48 Billion KRW | -18.15% |
| 2010 Q2 | 10.79 Billion KRW | -33.4% |
| 2010 Q1 | 16.2 Billion KRW | 35.73% |
| 2010 Q4 | 11.84 Billion KRW | 11.47% |
| 2010 Q3 | 10.62 Billion KRW | -1.52% |
| 2010 FY | 49.46 Billion KRW | 12.72% |
| 2009 FY | 43.88 Billion KRW | -0.84% |
| 2009 Q4 | 11.93 Billion KRW | 11.78% |
| 2009 Q3 | 10.68 Billion KRW | -0.88% |
| 2009 Q2 | 10.77 Billion KRW | 2.7% |
| 2009 Q1 | 10.49 Billion KRW | -11.51% |
| 2008 Q3 | 11.74 Billion KRW | 17.58% |
| 2008 Q4 | 11.85 Billion KRW | 0.97% |
| 2008 Q2 | 9.98 Billion KRW | -7.75% |
| 2008 FY | 44.25 Billion KRW | -5.16% |
| 2008 Q1 | 10.82 Billion KRW | 1.53% |
| 2007 Q2 | 12.77 Billion KRW | 0.45% |
| 2007 Q3 | 10.6 Billion KRW | -16.99% |
| 2007 Q1 | 12.71 Billion KRW | 0.0% |
| 2007 Q4 | 10.66 Billion KRW | 0.58% |
| 2007 FY | 46.66 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -47.011% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 76.688% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 75.051% |
| HANDOK Inc. | 153.76 Billion KRW | 54.823% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -0.368% |
| Yuhan Corporation | 489.94 Billion KRW | 85.821% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 77.369% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -66.235% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 88.63% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 3.494% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 60.11% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -73.441% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 25.743% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 39.448% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -47.011% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -63.564% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 7.436% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -18.458% |
| JW Holdings Corporation | 301.25 Billion KRW | 76.94% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 73.379% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 83.001% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 70.923% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 45.587% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -1.695% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -5.653% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 60.287% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -47.011% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 72.115% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 87.604% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 70.923% |
| Yuhan Corporation | 489.94 Billion KRW | 85.821% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 64.129% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -23.98% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 70.923% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 45.038% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 41.235% |
| CKD Bio Corp. | 25.19 Billion KRW | -175.715% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 68.708% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 57.927% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -4.594% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 45.587% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 80.192% |
| Boryung Corporation | 285.16 Billion KRW | 75.639% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 20.646% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 60.11% |
| JW Lifescience Corporation | 20.26 Billion KRW | -242.859% |